Hrt Financial LP Nuvation Bio Inc. Transaction History

Hrt Financial LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.96 - $1.53 $136,557 - $217,637	142,247 Added 1203.55%	154,066 $232,000
Q3 2023 Nov 13, 2023	BUY	$1.26 - $2.1 $14,891 - $24,819	11,819 New	11,819 $15,000
Q1 2023 May 12, 2023	SELL	$1.6 - $2.48 $357,587 - $554,260	-223,492 Reduced 67.33%	108,463 $180,000
Q4 2022 Feb 10, 2023	BUY	$1.68 - $2.5 $557,684 - $829,887	331,955 New	331,955 $637,000
Q2 2022 Aug 12, 2022	BUY	$3.24 - $5.85 $134,450 - $242,757	41,497 New	41,497 $134,000

152

123M

9.7K

6.5K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $480M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.